All In Biotech

Drug Trial Radar · NCT06767748

A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin

A Phase III Clinical Study Comparing the Efficacy and Safety of Once-weekly GZR4 Versus Once-daily Insulin Degludec With or Without Non-Insulin Antidiabetic Agents in Subjects With Type 2 Diabetes Mellitus (T2DM) Treated With Basal Insulin

Last checked: Nov 19, 2026Latest source record: Nov 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 620 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

620

Planned (sponsor's estimate)

Start

Feb 15, 2025

Primary completion

Feb 7, 2026

Study completion Feb 28, 2026

Sponsor

Lead sponsor
Gan & Lee Pharmaceuticals.Industry
Sponsor type
Industry
First posted
Jan 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will be conducted to compare the efficacy, safety and patient-reported outcome of once-weekly GZR4 and once-daily Insulin Degludec with or without Non-Insulin Antidiabetic Agents in subjects with Type 2 Diabetes Mellitus (T2DM) treated with basal insulin.

Conditions

  • Diabetes

Interventions

  • GZR4Drug

    GZR4 s.c., once-weekly,treat-to-target dose

  • insulin degludecDrug

    insulin degludec s.c.,once-daily,treat-to-target dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in HbA1cTime frame: From baseline (week 0) to week 26

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Gan & Lee Pharmaceuticals Shandong Co., Ltd.

    Linyi, Shandong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.